Goserelin Production Cost Reports

The report provides a detailed analysis essential for establishing a Goserelin production plant. It encompasses all critical aspects necessary for Goserelin production, including the cost of Goserelin production, Goserelin plant cost, Goserelin production costs, and the overall Goserelin production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Goserelin production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Goserelin is a synthetic gonadotropin-releasing hormone (GnRH) agonist. It is mainly utilised in pharmaceutical production as an active pharmaceutical ingredient (API) for sustained-release formulations like implants and microspheres, targeting hormone-dependent conditions such as advanced prostate cancer, breast cancer, endometriosis, uterine fibroids, and precocious puberty.

Additionally, manufacturers use GMP-grade liquid-phase peptide synthesis (LPPS) for large-scale API production, integrating PLGA-based technologies like solid-in-oil (S/O) or solid dispersion methods. These enable high entrapment efficiency (>90%), controlled release, and long-acting depots for intramuscular/subcutaneous delivery, reducing initial burst and serum fluctuations. The approach supports oncology and reproductive products such as Zoladex, with patents focusing on microsphere formulations for adenomyosis, infertility, and hysteromyoma.

The market demand for Goserelin is driven by the global rise in the cases of hormone-sensitive cancers, such as prostate and breast cancer, coupled with the increasing prevalence of endometriosis and uterine fibroids, which boost demand for its sustained-release formulations like Zoladex.

The improving healthcare infrastructure, cancer screening programs, government-funded oncology initiatives, and higher reimbursement coverage contribute to the market demand. Additional drivers include entrenched clinical guidelines (e.g., NCCN, EAU), preference for long-acting injectable GnRH agonists due to dosing convenience, and lifecycle strategies like device innovations and tender-based procurement. Industrial Goserelin procurement is heavily influenced by pricing pressures from patent expiries, enabling generic penetration that drives down costs in tender-driven markets like Asia-Pacific, Latin America, and Eastern Europe, while branded versions like Zoladex retain premium pricing in the US, Japan, and Europe due to clinician preference and reimbursement support.

Raw Material for Goserelin Production

According to the Goserelin production plant project report, the various raw materials for Goserelin production include protected amino acid monomers.

Production Process of Goserelin

The extensive Goserelin production cost report consists of the following major industrial production process:

1. Production via a hybrid fragment-condensation synthesis: The production process of Goserelin uses a hybrid fragment condensation strategy where protected peptide blocks are built by Fmoc SPPS on acid labile resins, then coupled in solution to assemble the full goserelin sequence more efficiently and with fewer side reactions. This convergent route enables parallel fragment production, reduces diketopiperazine formation and racemisation, and supports industrial scale up, after which the precursor undergoes C terminal azaglycine introduction, global deprotection (e.g., Pd/C hydrogenation or acidolysis), and RP HPLC purification to yield GMP grade goserelin acetate suitable for depot formulations.

Properties of Goserelin

Goserelin (C59H84N18O14) is a synthetic decapeptide analogue of GnRH with a molecular weight of 1269.43 g/mol (free base). It appears as a white to off-white lyophilised powder that is freely soluble in water and acidic solutions but sparingly soluble in neutral or basic media. Its acetate salt (C61H88N18O16, MW ~1327.5 g/mol) enhances pharmaceutical handling, with computed logP around -3.5 indicating high hydrophilicity suitable for subcutaneous implants, and multiple ionisable groups (pKa values spanning basic arginines ~12.5 and acidic carboxyls ~2-4) contributing to pH-dependent solubility and stability. The compound has good thermal stability under refrigeration (2-8 degree Celsius), resistance to enzymatic degradation due to D-Ser(tBu) at position 6 and C-terminal azaglycine hydrazide. It is prone to aggregation or hydrolysis in alkaline conditions, necessitating lyophilisation and inert packaging for GMP storage.